TRACON Pharmaceuticals to Present at the BTIG Virtual Biotechnology Conference

Rhea-AI Summary

TRACON Pharmaceuticals (TCON) announced that Dr. Charles Theuer, President and CEO, will give a corporate overview at the 2020 BTIG Virtual Biotechnology Conference on August 10 at 11:30 am EDT. TRACON specializes in developing targeted cancer therapies using a cost-effective, CRO-independent platform. Their clinical pipeline includes Envafolimab for sarcoma, TRC253 for prostate cancer, TRC102 for lung cancer, and TJ004309 for advanced solid tumors. The company seeks partnerships to enhance U.S. regulatory and commercialization efforts.

SAN DIEGO, Aug. 03, 2020 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (Nasdaq: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., announced today that Charles Theuer, M.D., Ph.D., President and CEO, will present a corporate overview at the 2020 BTIG Virtual Biotechnology Conference on Monday, August 10^th, at 11:30 am EDT.

To access a live webcast of the presentation, please visit the “Events and Presentations” page within the “Investors” section of the TRACON Pharmaceuticals website at www.traconpharma.com.

About TRACON

TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a subcutaneous PD-L1 single-domain antibody being developed for the treatment of sarcoma with the goal of initiating a registrational trial in the U.S. in the fourth quarter of 2020; TRC253, a small molecule drug candidate for the treatment of prostate cancer; TRC102, a Phase 2 small molecule drug candidate being developed for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors.  TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization.  In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S.  To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.

Company Contact:	Investor Contact:
Mark Wiggins	Andrew McDonald
Chief Business Officer	LifeSci Advisors LLC
(858) 251-3492	646-597-6987
mwiggins@traconpharma.com	Andrew@lifesciadvisors.com

FAQ

When is the TRACON Pharmaceuticals presentation at the BTIG Virtual Biotechnology Conference?

Dr. Charles Theuer will present at the BTIG Virtual Biotechnology Conference on August 10, 2020, at 11:30 am EDT.

What is TRACON Pharmaceuticals focused on developing?

TRACON Pharmaceuticals focuses on the development of novel targeted cancer therapeutics.

What is the product pipeline of TRACON Pharmaceuticals?

TRACON's pipeline includes Envafolimab, TRC253, TRC102, and TJ004309 for various cancer treatments.

How can I access the live webcast of the TRACON conference presentation?

You can access the live webcast on the 'Events and Presentations' page of TRACON's website.

What role does TRACON Pharmaceuticals play in corporate partnerships?

TRACON aims to lead U.S. regulatory and clinical development while sharing costs and risks in partnerships.